GEN Exclusives

More »

GEN News Highlights

More »
Jan 3, 2007

FivePrime and Centocor Partner on Osteoarthritis and Pulmonary Fibrosis Therapeutics

  • Five Prime Therapeutics and Centocor Research and Development will focus on novel therapeutic products to treat osteoarthritis and pulmonary fibrosis, under a worldwide collaborative research and license agreement.

    FivePrime will screen its comprehensive protein library against cell-based assays directed to osteoarthritis and fibrosis. Centocor will have exclusive rights to the proteins and targets identified in these screens.

    FivePrime will receive an upfront payment of $15 million comprised of cash and an equity investment by Johnson and Johnson Development (JJDC) and two years research funding from Centocor. Centocor will have exclusive worldwide rights to develop and commercialize products and targets discovered during the research term in exchange for future milestones and royalties.

    "With Centocor as a partner in these disease areas, we should be able to move the products of our discovery platform into clinical trials faster and more effectively," comments Lewis T. Williams, FivePrime's founder and executive chairman.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Should “Special K” Get Special Treatment?

In the near term, what is the best way to use ketamine in treating depression?